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TREATING the MOST COMMON
LIVER DISORDER
NON-ALCOHOLIC LIVER DISEASE, ALSO KNOWN AS FATTY LIVER
Disease, is the most common liver disorder in
western nations. Up to 30 percent of Americans
have some level of the disease, and it will soon
be the country’s leading cause for liver transplant.
As its name suggests, Fatty Liver Disease begins
simply with storage of excess fat in the liver, but can
progress into serious liver inflammation and to the
extensive scarring of liver tissue known as cirrhosis.
Currently, biomedical researchers have a limited
understanding of what causes the disease and drives
its progression. Dina Halegoua-DeMarzio, MD,
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associate professor of medicine and director
of Jefferson’s Fatty Liver Center, and her
colleagues are working to uncover the cellular
mechanisms underlying the disease, in part by
identifying associated conditions. “Although
Fatty Liver patients are often overweight, suffer
insulin resistance and diabetes, and have high
cholesterol,” Dr. Halegoua-DeMarzio explains,
“we have found further associations with celiac
disease and binge-eating disorders, and are
investigating the exact relationships and causeand-effect connections among these conditions.”

There are no non-invasive methods of diagnosing
the emerging condition. That is why the Fatty Liver
Center is testing

new diagnostic methods

and conducting an array of clinical trials.

There is also much to be learned on the clinical
level: There are no non-invasive methods of
diagnosing the emerging condition—at present,
liver biopsies are necessary—and no medications
known to prevent or cure the disease. That is why
the Fatty Liver Center is testing new diagnostic
methods and conducting an array of clinical trials
of potential therapies. Among the most promising
drug studies are two phase III trials of treatments
for patients with moderate liver scarring, and two
phase II trials of therapies that show evidence of
reducing liver fat levels and removing cholesterols
that contribute to fat build-up in the liver. 
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